XML 31 R24.htm IDEA: XBRL DOCUMENT v3.26.3
License Agreements and Clinical Development Collaboration - Additional Information (Details)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
Oct. 19, 2020
USD ($)
Product
$ / shares
shares
Aug. 03, 2020
USD ($)
Product
$ / shares
shares
Sep. 30, 2026
USD ($)
shares
Sep. 30, 2025
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2026
USD ($)
shares
Sep. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
shares
May 23, 2025
$ / shares
shares
License Agreements [Line Items]                  
Number of licensed products obliged to develop and commercialize | Product 1 1              
Upfront payment shares issued | shares     103,865,706     103,865,706   98,528,949  
Upfront payment value     $ 11     $ 11   $ 11  
Issue price per share | $ / shares                 $ 6.5
Research and Development Expense (Excluding Acquired in Process Cost)     $ 43,358 $ 28,773   111,091 $ 83,962    
Proceeds from issuance of common stock and pre-funded warrants           $ 60,881 $ 244,369    
Common Stock                  
License Agreements [Line Items]                  
Upfront payment shares issued | shares                 14,130,313
Mirati Therapeutics, Inc                  
License Agreements [Line Items]                  
Number of period the agreement in effect   10 years              
Mirati Therapeutics, Inc | Private Placement | Common Stock                  
License Agreements [Line Items]                  
Upfront payment shares issued | shares   588,235              
Upfront payment value   $ 13,000              
Issue price per share | $ / shares   $ 34              
Premium percentage   10.00%              
Stock transfer restrictions period   18 months              
Voronoi Inc.                  
License Agreements [Line Items]                  
Upfront cash payment $ 5,000                
Voronoi Inc. | Development And Regulatory Milestone                  
License Agreements [Line Items]                  
Asset acquisition contingent consideration, liability 111,000                
Voronoi Inc. | Commercial Milestone                  
License Agreements [Line Items]                  
Asset acquisition contingent consideration, liability 225,000                
Voronoi Inc. | Success Based Milestones                  
License Agreements [Line Items]                  
Asset acquisition contingent consideration, liability $ 272,000                
Voronoi Inc. | In Process Research and Development [Member]                  
License Agreements [Line Items]                  
License agreement cash payment related to acquired assets charge         $ 5,000        
Voronoi Inc. | Private Placement | Common Stock                  
License Agreements [Line Items]                  
Upfront payment shares issued | shares 283,259                
Upfront payment value $ 6,800                
Issue price per share | $ / shares $ 28.24                
Premium percentage 25.00%